+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Short Bowel Syndrome Market, Growth Hormone, Glutamine, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

  • ID: 5005245
  • Report
  • January 2020
  • Region: Global
  • 176 pages
  • Transparency Market Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Ardelyx, Inc.
  • Merck KGaA
  • Nutrinia Ltd
  • OxThera
  • Sancilio & Company, Inc.
  • Zealand Pharma A/S
  • MORE
Short Bowel Syndrome Market - Scope of the Report

This report on the global short bowel syndrome market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the market during the forecast period from 2019 to 2027. The report provides the revenue of the short bowel syndrome market for the period 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the short bowel syndrome market for the forecast period. The report has been prepared after an extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global short bowel syndrome market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have also employed a combination of top-down and bottom-up approaches to study various phenomena in the short bowel syndrome market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Additionally, the report sheds light on the changing competitive dynamics in the short bowel syndrome market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the short bowel syndrome market. The next section of the short bowel syndrome report highlights the USPs, which include drivers & restraints impact analysis, value chain analysis; short bowel syndrome disease overview, short bowel syndrome epidemiology, rare diseases prevalence, overview of clinical trials for short bowel syndrome, qualitative analysis of glp-2 product, research & development cost analysis, impact analysis of clinical trials cost on orphan drugs, cost analysis of therapies using orphan drugs, approved U.S. orphan indications, 1983–2015, approved European orphan indications, 2019, pricing analysis, orphan drugs – price volume analysis, justifications for the high cost of Gattex & Teduglutide, regulations scenario assessment, flow chart guide to determine eligibility for standard orphan designation in Australia, impact analysis of regulatory scenario assessment, comparative analysis of orphan drug policies, orphan drug manufacturing companies, acquisitions timeline, and SWOT analysis.

The report analyzes the short bowel syndrome market in terms of drug class and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2027 has been provided. These valuable insights would help market stakeholders in making informed business decisions for investments in the short bowel syndrome market.

Key Questions Answered
  • What is the sales/revenue generated by different short bowel syndrome (SBS) across all the regions during the forecast period?
  • What are the major drivers, restraints, and opportunities in the market?
  • Which region is set to expand at the fastest CAGR during the forecast period?
  • Which segment will have the highest revenue globally in 2027 and which product will expand at the fastest CAGR during the forecast period?
Research Objectives and Research Approach

The comprehensive report on the short bowel syndrome market begins with an overview of the market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives of the study and healthcare compliances laid down by accredited agencies in the purview of research in the short bowel syndrome market. It is followed by market introduction, market dynamics, and an overview of the short bowel syndrome market, which includes analysis of market drivers, restraints, and trends affecting the growth of the market. Furthermore, Y-o-Y analysis with elaborate insights has been provided to understand the Y-o-Y trends of the short bowel syndrome market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section further divided into small sections. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

Revenue generated by key short bowel syndrome market manufacturers has been mapped to ascertain the size of the short bowel syndrome market in terms of value. The forecast presented here assesses the total revenue generated by dermatome devices. In order to provide an accurate forecast, we initiated by sizing up the current short bowel syndrome market with the help of the parent market.

The report also delves into the competitive landscape of the short bowel syndrome market. Key players operating in the short bowel syndrome treatment market have been identified, and each one of these has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the short bowel syndrome treatment market report.

Key players operating in the short bowel syndrome market include Shire plc (Takeda Pharmaceutical Company Limited), Zealand Pharma A/S, Sancilio & Company, Inc., OxThera, Nutrinia Ltd., Ardelyx, Inc., Emmaus Life Sciences, Inc., GLyPharma Therapeutic, Inc. (Pfizer Inc.), Merck KGaA, and Naia Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Ardelyx, Inc.
  • Merck KGaA
  • Nutrinia Ltd
  • OxThera
  • Sancilio & Company, Inc.
  • Zealand Pharma A/S
  • MORE

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights

2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology

3. Executive Summary
3.1. Global Short Bowel Syndrome Market: Market Snapshot

4. Market Overview
4.1. Global Short Bowel Syndrome Market: Type Overview
4.2. Global Short Bowel Syndrome Market: Key Industry Developments
4.3. Market Dynamics
4.4. Drivers and Restraints Snapshot Analysis
4.5. Drivers
4.5.1. High cost of parenteral nutrition increases demand for SBS drugs
4.5.2. Favorable reimbursement scenario
4.6. Restraints
4.6.1. Side effects associated with SBS drugs
4.6.2. Non-availability of approved drugs globally
4.7. Opportunities
4.8. Global Short Bowel Syndrome Market Revenue Projections (US$ Mn), 2017-2027

5. Key Insights
5.1. Drivers & Restraints Impact Analysis
5.2. Value Chain Analysis
5.3. Short Bowel Syndrome: Disease Overview
5.4. Short Bowel Syndrome: Epidemiology
5.5. Rare Diseases Prevalence
5.6. Overview of Clinical Trials for Short Bowel Syndrome
5.7. Qualitative Analysis of GLP-2 Product
5.8. Research & Development Cost Analysis
5.9. Impact Analysis of Clinical Trials Cost on Orphan Drugs
5.10. Cost Analysis of Therapies using Orphan Drugs
5.11. Approved U.S. Orphan Indications, 1983-2015
5.12. Approved European Orphan Indications, 2019
5.13. Pricing Analysis
5.14. Orphan Drugs - Price Volume Analysis
5.15. Justifications for the High Cost of Gattex & Teduglutide
5.16. Regulations Scenario Assessment
5.17. Flow Chart Guide to Determine Eligibility for Standard Orphan Designation in Australia
5.18. Impact Analysis of Regulatory Scenario Assessment
5.19. Comparative Analysis of Orphan Drug Policies
5.20. Orphan Drug Manufacturing Companies - Acquisitions Timeline
5.21. Orphan Drugs Market- Swot Analysis

6. Global Short Bowel Syndrome Market Analysis, by Drug Class
6.1. Introduction
6.2. Global Short Bowel Syndrome Market Value and Forecast, by Drug Class
6.2.1. Glucagon-like Peptide-2 (GLP-2)
6.2.2. Growth Hormone
6.2.3. Glutamine
6.2.4. Others
6.3. Global Short Bowel Syndrome Market Analysis, by Drug Class
6.4. Global Short Bowel Syndrome Market Attractiveness Analysis, by Drug Class

7. Global Short Bowel Syndrome Market Analysis, by Region
7.1. Global Short Bowel Syndrome Market Value and Forecast, by Region, 2017-2027
7.1.1. North America
7.1.2. Europe
7.1.3. Japan
7.1.4. Rest of the World
7.2. Global Short Bowel Syndrome Market Analysis, by Region
7.3. Global Short Bowel Syndrome Market Attractiveness Analysis, by Region

8. North America Short Bowel Syndrome Market Analysis
8.1. North America Short Bowel Syndrome Market
8.2. North America Short Bowel Syndrome Market Overview
8.3. North America Short Bowel Syndrome Market Value and Forecast, by Drug Class
8.3.1. Glucagon-like Peptide-2 (GLP-2)
8.3.2. Growth Hormone
8.3.3. Glutamine
8.3.4. Others
8.4. North America Short Bowel Syndrome Market Forecast, by Country
8.4.1. U.S.
8.4.2. Canada
8.5. North America Short Bowel Syndrome Market Attractiveness Analysis
8.5.1. By Drug Class
8.5.2. By Country

9. Europe Short Bowel Syndrome Market Analysis
9.1. Europe Short Bowel Syndrome Market
9.2. Europe Short Bowel Syndrome Market Overview
9.3. Europe Short Bowel Syndrome Market Value and Forecast, by Drug Class
9.3.1. Glucagon-like Peptide-2 (GLP-2)
9.3.2. Growth Hormone
9.3.3. Glutamine
9.3.4. Others
9.4. Europe Short Bowel Syndrome Market Forecast, by Country/Sub-region
9.4.1. U.K.
9.4.2. France
9.4.3. Germany
9.4.4. Spain
9.4.5. Italy
9.4.6. Rest of Europe
9.5. Europe Short Bowel Syndrome Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Country/Sub-region

10. Japan Short Bowel Syndrome Market Analysis
10.1. Japan Short Bowel Syndrome Market Key Findings
10.2. Japan Short Bowel Syndrome Market Overview
10.3. Japan Short Bowel Syndrome Market Value and Forecast, by Drug Class
10.3.1. Glucagon-like Peptide-2 (GLP-2)
10.3.2. Growth Hormone
10.3.3. Glutamine
10.3.4. Others
10.4. Japan Short Bowel Syndrome Market Attractiveness Analysis, by Drug Class

11. Rest of the World Short Bowel Syndrome Market Analysis
11.1. Rest of the World Short Bowel Syndrome Market Key Findings
11.2. Rest of the World Short Bowel Syndrome Market Overview
11.3. Rest of the World Short Bowel Syndrome Market Value and Forecast, by Drug Class
11.3.1. Glucagon-like Peptide-2 (GLP-2)
11.3.2. Growth Hormone
11.3.3. Glutamine
11.3.4. Others
11.4. Rest of the World Short Bowel Syndrome Market Analysis, by Country/Sub-region
11.4.1. China
11.4.2. India
11.4.3. Australia/New Zealand
11.4.4. Middle East
11.4.5. Brazil

12. Competitive Landscape
12.1. Company Profiles
12.1.1. Shire plc (Takeda Pharmaceutical Company Limited)
12.1.1.1. Overview (HQ, Employee Strength, Business Segments)
12.1.1.2. Financials
12.1.1.3. Recent Developments
12.1.1.4. Strategy
12.1.2. Zealand Pharma A/S
12.1.2.1. Overview (HQ, Employee Strength, Business Segments)
12.1.2.2. Financials
12.1.2.3. Recent Developments
12.1.2.4. Strategy
12.1.3. Sancilio & Company, Inc.
12.1.3.1. Overview (HQ, Employee Strength, Business Segments)
12.1.3.2. Recent Developments
12.1.3.3. Strategy
12.1.4. OxThera
12.1.4.1. Overview (HQ, Employee Strength, Business Segments)
12.1.4.2. Recent Developments
12.1.4.3. Strategy
12.1.5. Nutrinia Ltd
12.1.5.1. Overview (HQ, Employee Strength, Business Segments)
12.1.5.2. Recent Developments
12.1.5.3. Strategy
12.1.6. Ardelyx, Inc.
12.1.6.1. Overview (HQ, Employee Strength, Business Segments)
12.1.6.2. Financials
12.1.6.3. Recent Developments
12.1.6.4. Strategy
12.1.7. Emmaus Life Sciences, Inc.
12.1.7.1. Overview (HQ, Employee Strength, Business Segments)
12.1.7.2. Financials
12.1.7.3. Recent Developments
12.1.7.4. Strategy
12.1.8. GLyPharma Therapeutic, Inc. (Pfizer Inc.)
12.1.8.1. Overview (HQ, Employee Strength, Business Segments)
12.1.8.2. Financials
12.1.8.3. Recent Developments
12.1.8.4. Strategy
12.1.9. Merck KGaA
12.1.9.1. Overview (HQ, Employee Strength, Business Segments)
12.1.9.2. Financials
12.1.9.3. Recent Developments
12.1.9.4. Strategy
12.1.10. Naia Pharmaceuticals, Inc.
12.1.10.1. Overview (HQ, Employee Strength, Business Segments)
12.1.10.2. Recent Developments
12.1.10.3. Strategy    

List of Tables
Table 1 Overview of Clinical Trials for Short Bowel Syndrome (1/2)
Table 2 Overview of Clinical Trials for Short Bowel Syndrome (2/2)
Table 3 Orphan Drugs Research & Development Cost (US$ Mn), 2014-2018
Table 4 Impact Analysis of Clinical Trials Cost on Orphan Drugs (1/2)
Table 5 Impact Analysis of Clinical Trials Cost on Orphan Drugs (2/2)
Table 6 Comparative Analysis of Orphan Drug Policies
Table 7 Global Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
Table 8 Global Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Region, 2019-2027
Table 9 North America Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
Table 10 North America Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Country, 2017-2027
Table 11 Europe Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
Table 12 Europe Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
Table 13 Japan Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027    

List of Figures
Figure 1: Market Size Estimation Methodology
Figure 2: Market Snapshot Global Short Bowel Syndrome Market
Figure 3: Global Short Bowel Syndrome Market Revenue (US$ Mn) (2018)
Figure 4: Global Short Bowel Syndrome Market Top 3 Trends
Figure 5: Global Short Bowel Syndrome Market Key Drivers, Restraints, and Trends
Figure 6: Global Short Bowel Syndrome Market Value (US$ Mn) and Distribution by Geography, 2018 and 2027
Figure 7: Drivers and Restraints Snapshot Analysis (1/2)
Figure 8: Drivers and Restraints Snapshot Analysis (2/2)
Figure 9: Opportunity Analysis Global Short Bowel Syndrome Market
Figure 10: Global Short Bowel Syndrome Market Value (US$ Mn) and Forecast, 2017-2027
Figure 11: Porter’s Five Force Analysis Global Short Bowel Syndrome Market
Figure 12: Drivers Impact Analysis Short Bowel Syndrome (SBS) Market
Figure 13: Restraints Impact Analysis Short Bowel Syndrome (SBS) Market
Figure 14: Value Chain: Short Bowel Syndrome (SBS) Market (Gattex)
Figure 15: Pathophysiology Short Bowel Syndrome
Figure 16: Causes of SBS in Neonates in Neonatal Intensive Care Units (NICU)
Figure 17: Causes of SBS in Adults
Figure 18: Prevalence of Orphan (rare) Diseases
Figure 19: Amino Acid Sequence of Teduglutide (GLP-2)
Figure 20: Amino Acid Sequence of Natural GLP-2
Figure 21: Mode of Action of GLP-2 Product
Figure 22: Orphan Drugs Research & Development Cost (US$ Mn), 2014-2018
Figure 23: U.S. Average Cost of Therapies using Orphan Drugs per Patients (US$/Patients/Year)
Figure 24: Approved U.S. Orphan Indications, 1983-2015
Figure 25: Approved European Orphan Indications, 2019
Figure 26: Factors Contributing to Orphan Drugs Pricing Decision
Figure 27: Pricing of Certain Orphan Drugs (US$ per patient per year)
Figure 28: Factors for High Prices of Orphan Drugs
Figure 29: Orphan Drugs - Price Volume Analysis
Figure 30: Justifications for the High Cost of Gattex & Teduglutide
Figure 31: U.S. Regulatory Scenario Assessment Flow Chart
Figure 32: Regulatory Approval Process- Europe
Figure 33: Regulatory Approval Process- Japan
Figure 34: Flow Chart Guide to Determine Eligibility for Standard Orphan Designation in Australia (excluding financial viability and new dosage form medicines)
Figure 35: Impact Analysis of Regulatory Scenario Assessment
Figure 36: Orphan Drugs Market- Swot Analysis
Figure 37: Introduction - Global Short Bowel Syndrome (SBS) Market, by Drug Class (2/2)
Figure 38: Global Short Bowel Syndrome (SBS) Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 39: Global Short Bowel Syndrome (SBS) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Glucagon-like Peptide-2 (GLP-2), 2017-2027
Figure 40: Global Short Bowel Syndrome (SBS) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Growth Hormone, 2017-2027
Figure 41: Global Short Bowel Syndrome (SBS) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Glutamine, 2017-2027
Figure 42: Global Short Bowel Syndrome (SBS) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027
Figure 43: Global Short Bowel Syndrome (SBS) Market Attractiveness Analysis, by Drug Class, 2019-2027
Figure 44: Global Market Scenario
Figure 45: Introduction - Global Short Bowel Syndrome (SBS) Market: by Region (2/2)
Figure 46: Global Short Bowel Syndrome (SBS) Market Value Share Analysis, by Region, 2018 and 2027
Figure 47: Global Short Bowel Syndrome (SBS) Market Attractiveness Analysis, by Region
Figure 48: North America Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, 2017-2027
Figure 49: North America Short Bowel Syndrome (SBS) Market Attractiveness Analysis, by Drug Class, 2019-2027
Figure 50: North America Short Bowel Syndrome (SBS) Market Attractiveness Analysis, by Country, 2019-2027
Figure 51: North America Short Bowel Syndrome (SBS) Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 52: North America Short Bowel Syndrome (SBS) Market Value Share Analysis, by Country, 2018 and 2027
Figure 53: Europe Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, 2017-2027
Figure 54: Europe Short Bowel Syndrome (SBS) Market Attractiveness Analysis, by Drug Class, 2019-2027
Figure 55: Europe Short Bowel Syndrome (SBS) Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
Figure 56: Europe Short Bowel Syndrome (SBS) Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 57: Europe Short Bowel Syndrome (SBS) Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 58: Japan Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, 2017-2027
Figure 59: Japan Short Bowel Syndrome (SBS) Market Attractiveness Analysis, by Drug Class
Figure 60: Japan Short Bowel Syndrome (SBS) Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 61: Rest of the World (excluding Japan) Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, 2017-2027
Figure 62: Global Short Bowel Syndrome (SBS) Market Share Analysis, by Company (2018)
Figure 63: Shire plc Internal Medicine Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2017
Figure 64: Shire plc Breakdown of Net Sales (%), by Region/Country, 2017
Figure 65: Shire plc Breakdown of Net Sales (%), by Business Segment, 2017
Figure 66: Shire plc Swot Analysis
Figure 67: Zealand Pharma A/S Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018
Figure 68: Zealand Pharma A/S Swot Analysis
Figure 69: Sancilio & Company, Inc. Swot Analysis
Figure 70: OxThera Swot Analysis
Figure 71: Nutrinia Ltd. Swot Analysis
Figure 72: Ardelyx, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2018
Figure 73: Ardelyx, Inc. Breakdown of Net Sales, by Revenue Type, 2018
Figure 74: Ardelyx, Inc. Research & Development Cost 2015 -2017
Figure 75: Ardelyx, Inc. Swot Analysis
Figure 76: Emmaus Life Sciences, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2016-2018
Figure 77: Emmaus Life Sciences, Inc. R&D Spending and Sales & Marketing Expenses (US$ Mn), Company Level, 2017-2018
Figure 78: Emmaus Life Sciences, Inc. Breakdown of Net Sales, by Service Type, 2018
Figure 79: Emmaus Life Sciences, Inc. Swot Analysis
Figure 80: Pfizer Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015-2018
Figure 81: Pfizer Inc. Breakdown of Net Sales, by Region/Country, 2018
Figure 82: Pfizer Inc. R&D Expenses (US$ Bn) and Y-o-Y Growth (%), 2015-2018
Figure 83: Pfizer Inc. Breakdown of Net Sales, by Business Segment (%), 2018
Figure 84: Swot Analysis (Pfizer Inc.)
Figure 85: Merck KGaA Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018
Figure 86: Merck KGaA R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2017
Figure 87: Merck KGaA Breakdown of Net Sales (%), by Region, 2018
Figure 88: Merck KGaA Breakdown of Net Sales (%), by Business Segment, 2017
Figure 89: Merck KGaA Swot Analysis
Figure 90: Naia Pharmaceuticals, Inc. Swot Analysis

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Shire plc (Takeda Pharmaceutical Company Limited)
  • Zealand Pharma A/S
  • Sancilio & Company, Inc.
  • OxThera
  • Nutrinia Ltd
  • Ardelyx, Inc.
  • Emmaus Life Sciences, Inc.
  • GLyPharma Therapeutic, Inc. (Pfizer Inc.)
  • Merck KGaA
  • Naia Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll